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The amyloidoses comprise a heterogeneous group of diseases in which 1 out of more than 25 human
proteins aggregates into characteristic beta-sheet ﬁbrils with some unique properties. Aggregation is
nucleation dependent. Among the known amyloid-forming constituents is the prion protein, well
known for its ability to transmit misfolding and disease from one individual to another. There is
increasing evidence that other amyloid forms also may be transmissible but only if certain
prerequisites are fulﬁlled. One of these forms is systemic AA-amyloidosis in which an acute-phase
reactant, serum AA, is over-expressed and, possibly after cleavage, aggregates into amyloid ﬁbrils,
causing disease. In a mouse model, this disorder can easily be transmitted from one animal to another
both by intravenous and oral routes. Also, synthetic amyloid-like ﬁbrils made from deﬁned small
peptides have this property, indicating a prion-like transmission mechanism. Even some ﬁbrils
occurring in the environment can transmit AA-amyloidosis in the murine model. AA-amyloidosis is
particularly common in certain areas of Papua New Guinea, probably due to the endemicity of
malaria and perhaps genetic predisposition. Now, when kuru is disappearing, more interest should be
focused on the potentially lethal systemic AA-amyloidosis.
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1. INTRODUCTION
It has been increasingly acknowledged that misfolding
and aggregation of proteins into what we call amyloid is
a very common phenomenon and associated with
several different disorders. Amyloid is a generic name
for in vivo formed ﬁbrillar deposits, characteristic of a
number of diseases and which have in common
misfolding of a protein with a high degree of beta-
structure and which then aggregate into typical ﬁbrils
of undetermined length. The ﬁbrils are remarkably
similar in spite of very varying protein nature. Typical
of the ﬁbrils is their resistance to degradation and
adoption of particular binding properties, e.g. to
different dyes such as thioﬂavine T and Congo red.
Amyloid is thus a heterogeneous substance and in
humans more than 25 different proteins are known to
occur in this form, each typical of one or a few clinical
conditions (Westermark et al. 2007). The amyloid
can either be found in one tissue (local) or in many
organs around the body (systemic). The local forms
are most common and often found in the central
nervous system, the cardiovascular system or in some
endocrine organs.
2. AMYLOIDOSIS IN PAPUA NEW GUINEA
Deposits of amyloid occur in prion diseases including
kuru (Zigas & Gajdusek 1959) and are typical of some
common maladies such as Alzheimer’s disease and
type 2 diabetes. These are two disorders expected to
increase rapidly in Papua New Guinea when life
expectancy increases and a western lifestyle is adopted
(Hodge et al. 1995). Consequently, problems concern-
ing pathogenesis and importance of amyloid are highly
relevant also to Papua New Guinea.
The systemic amyloidoses comprise aheterogeneous
group of disorders in which amyloid deposits are
formed from a circulating precursor, usually synthe-
sized in one tissue but giving rise to deposits in many
organs of the body. At least 12 different proteins have
this property and each is characteristic of one or a few
clinical syndromes. Most systemic amyloidoses are life-
threatening disorders. One of the most common is
reactive (secondary or AA-) amyloidosis. The ﬁbril is
derived from the acute-phase reactant apolipoprotein
serum AA (SAA), whose expression in the liver is under
the control of interleukin (IL)-1, IL-6 and tumour
necrosis factor (TNF)-alpha. AA-amyloidosis is
thereby a consequence of some chronic inﬂammatory
disorders, notably infectious diseases, such as tuber-
culosis and leprosy, and rheumatic inﬂammations,
particularly rheumatoid arthritis. The major symptoms
in AA-amyloidosis come from the kidneys.
Systemic AA-amyloidosis occurs worldwide but has
been reported to be particularly prevalent in certain
areas of Papua New Guinea (McAdam et al. 1996).
Cooke & Champness (1970) reported an autopsy series
of 1101 individuals with a prevalence of 7.3 per cent of
systemic amyloidosis, which is uniquely high. At that
time, determination of type was uncertain and their
conclusion that approximately 50 per cent of these
cases were of ‘primary’ type was probably wrong. Most
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dosis. In order to explain the high prevalence, these
authors suggested that some hereditary factor may be
important in the pathogenesis. AA-amyloidosis in
Papua New Guinea is not rare in children, in whom a
characteristic hallmark may be amyloid goitre com-
bined with renal symptoms, an uncommon com-
bination elsewhere (Cooke & Champness 1972).
Cooke & Champness could not ﬁnd a cause of
amyloidosis such as leprosy or tuberculosis in approxi-
mately 50 per cent of their cases. At that time, malaria
was not regarded as a possible cause. It became
apparent that AA-amyloidosis was very prevalent
among the Anga people in the upper Watut Valley but
much more uncommon in the same linguistic group in
the highland area near Aseki (see McAdam et al. 1980).
A main difference between these two groups of people
was the very high prevalence of malaria with tropical
splenomegaly syndrome in the Watut Valley (McAdam
1976). McAdam used the newly developed subcu-
taneous fat needle biopsy (Westermark & Stenkvist
1973) for a unique point prevalence study and found 8
with amyloidosis among 76 (10.5%) biopsied individ-
uals in the Watut Valley area but none out of 72 among
the highlanders (McAdam et al. 1980). At that time,
the AA-nature of this amyloidosis had been shown
(Anders et al. 1976). Again, malaria was suspected to
be a main cause of the amyloid, although some
hereditary factor was suspected to be important as well.
In 1995, we performed a research tour, led by Dr
Keith P. W. J. McAdam, to Goroka (ﬁgure 1)a n dt o
Watut Valley, Papua New Guinea, for further studies of
AA-amyloidosis, particularly regarding possible heredi-
taryfactors.Althoughnotallobjectiveswerereached,we
identiﬁed, by protein sequence analysis of puriﬁed
protein AA from one patient, a previously undescribed
subspecies, derived from an SAA variant that was
designated SAA1d (Westermark et al. 1996). Human
acute-phase SAA is expressed by two different genes,
SAA1 and SAA2, and both occur with allelic variants.
SAA1a is most commonly found in amyloid ﬁbrils in
Caucasians and Asiatic people. In mice, two closely
relatedSAAallelicformsoccurbutonlyoneformsﬁbrils
and, hypothetically, the human SAA1d may be more
amyloidogenic than other variants, making individuals
who express this type more susceptible to develop
amyloidosis. Direct biochemical proof is still missing,
however, and as far as we know, no further studies have
been performed. More studies on the occurrence of this
SAA allelic variant are therefore warranted.
3. SYSTEMIC AMYLOIDOSIS AS A
TRANSMISSIBLE CONDITION
In spite of a chronic inﬂammatory disease with
persistent high plasma concentration of SAA, only
some individuals develop AA-amyloidosis, even after
a very long time. According to the above, one reason
could be the expression of different SAA alleles.
Another possibility may be in vivo ﬁbril inhibitors, yet
to be discovered. Another intriguing possibility is a
seeding mechanism of AA- or other ﬁbrils. There is no
proof of this possibility in humans, but there is
compelling evidence of this mechanism in the mouse.
In many strains of mice, it is easy to induce a systemic
AA-amyloidosis which is very similar to the human
form. This can be done by chronic or repeated
inﬂammatory challenge, either infectious or non-
infectious. In the latter Freund’s adjuvant, casein or
silver nitrate is most often used. After a lag phase of
several weeks or months, the animals develop AA-
deposits ﬁrst in the spleen, followed by the liver,
kidneys and other organs. In 1966, Ranløv & Werdelin
showed that transplantation of cells from an amyloi-
dotic mouse to an inﬂamed animal drastically reduced
the amyloid lag phase in the recipient (Werdelin &
Ranløv 1966). In further experiments, Ranløv and
co-workers could show that living cells are not
necessary, but extracts from amyloid-containing tissues
have the same properties (Hardt & Ranløv 1976). The
active principle, later called ‘amyloid enhancing factor,
AEF’, was for a long time elusive and the subject of a
number of studies. There were many suggestions
including glycoproteins and enzymes. Niewold et al.
(1987) came to the conclusion that the AEF-activity
was exerted by small fragments of amyloid ﬁbrils. That
ﬁts well with our ﬁndings that the extract of puriﬁed
mouse AA-amyloid is very potent and reduces the lag
time drastically even when given at extremely low
dose (Lundmark et al. 2002). In this way, murine
AA-amyloidosis is transmissible but only when the
recipient is prone to develop this disease. Although the
mechanism is prion-like, there is a fundamental
difference between prion diseases and other conditions
characterized by amyloid in that, as far as we know,
there must be an underlying abnormality in the latter,
resulting in a sufﬁcient concentration of an amyloid-
prone protein. This deviation from normal can be over-
expression of a protein, a point mutation resulting in
amino acid substitution or deletion or abnormal
cleavage of the ﬁbril protein precursor, or more.
4. CROSS-SEEDING AS A MECHANISM IN
AMYLOIDOSIS
Cross-seeding as used in this communication means
that one biochemical form ofﬁbrils induces aggregation
of another protein to amyloid. Seeding in vitro has a
high degree of speciﬁcity and substitution of one amino
acid residue can profoundly affect seeding capacity
Figure 1. At the Papua New Guinea Institute of Medical
Research, Goroka, 1995. In the middle are Dr McAdam and
Dr Alpers.
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Phil. Trans. R. Soc. B (2008)(Krebs et al. 2004; O’Nuallian et al. 2004). Never-
theless, ﬁbrils from Ab peptide may seed amyloid
formation from the unrelated peptide, islet amyloid
polypeptide (IAPP; O’Nuallian et al. 2004), in spite of
only approximately 25 per cent identity.
We were able to show that synthetic ﬁbrils made
from deﬁned small peptides, corresponding to parts of
known amyloid ﬁbril proteins, reduce the lag time
signiﬁcantly in the murine AA-amyloidosis system
(Ganowiak et al. 1994; Johan et al. 1998). In these
experiments, small amounts of ﬁbrils were injected
intravenously in the tail vein of mice given an
inﬂammatory challenge at the same time. These ﬁbrils
co-localized with the ﬁrst amyloid deposits that
appeared in the marginal zone of splenic lymph
follicles. Also, small aggregates of synthetic ﬁbrils
were trapped in lung capillaries and these contained
protein AA as well, which indicates a direct elongation
of the synthetic materials by this protein, resulting in
mixed ﬁbrils (Johan et al. 1998). In nature, there are
many examples of cross-beta-sheet ﬁbrils with proper-
ties of amyloid, including Bombyx mori silk, Sup 35
from Saccharomyces and curli from Escherichia coli.A l l
these also exert AEF properties in the murine
AA-amyloidosis model (Lundmark et al. 2005).
Finally, in collaboration with S. Zhang, MIT,
Cambridge, MA, we have studied the effects of
amyloid-like ﬁbrils, made from non-natural short
peptides intended for nano-technology, and found
that these also can speed up the development of
AA-amyloidosis in the same system (P. Westermark,
S. Zhang & G. T. Westermark, unpublished results).
However, in all these examples with synthetic peptides
and naturally occurring amyloid-like ﬁbrils, the lag
phase was longer than when native murine AA-ﬁbrils
are used and, typically, a number of animals did not
develop amyloidosis at all during the observation time.
In this respect, the situation resembles the species
barrier described for experimental transmission of
prion diseases (Vanik et al. 2004; Scott et al. 2005).
5. TRANSMISSION OF AMYLOIDOSIS WITH
NATIVE AMYLOID FIBRILS
Transmission of AA-amyloidosis to sensitive mice is
efﬁcient with a very low dose of material. This has
also been seen with murine systemic apoliprotein
A-II-derived amyloidosis (Ge et al. 2007). In addition,
transmission of AA-amyloidosis has been found in
hamster (Niewold et al. 1987), mink (Sørby et al. 2008)
and duck (Benditt 1976). The latter two show that
transmission is not restricted to rodents and there is no
reason to believe that it could not happen in humans as
well. It should be noted that transmission in mice is
efﬁcientnotonlybyintravenousinjectionbutalsobythe
oral or nasal route (Lundmark et al. 2002). The risk of
transmission is probably very low for human systemic
amyloidoses, but the following patient story illustrates
that this possibility cannot be completely ignored.
A 50-year-old woman underwent a renal cadaveric
transplantation. The history of the donor was not quite
well known and the kidney came from another
European country. After transplantation, the concen-
tration of creatinine in plasma did not decrease as
expected. A renal biopsy was performed and that
showed pronounced amyloid deposits in the glomeruli
(ﬁgure 2). A subsequent biopsy veriﬁed this ﬁnding.
Due to lack of material, no determination of amyloid
type could be performed. The patient was lost during
follow-up and the outcome is not known.
From this case history, it is obvious that trans-
mission of amyloidosis between humans is possible.
Given the low dose needed in the mouse model,
contaminated surgical instruments may be a hazard;
but no such case has yet been described.
Systemic AA-amyloidosis is not limited to humans
and experimental animals, but spontaneously occurring
disease is known from many mammalian and avian
species (Zschiesche & Jakob 1989; Johnson et al. 1996).
Duringthelastyears,ithasbecomeevidentthatsystemic
AA-amyloidosis is not rare in animals used as human
food. Thus, Tojo et al. (2005) found a surprisingly high
incidenceoftheconditioninslaughteredcattle inJapan.
It is also well known that AA-amyloidosis is prevalent in
domesticducksandgeese(Brassard1965;Zschiesche&
Jakob 1989). In a recent study, Solomon et al. found
AA-amyloid in commercially available duck liver and
foie gras (Solomon et al. 2007), clearly demonstrating
that this is somethingfrequentlyeaten incertain partsof
the world. Extract of this liver amyloid enhanced the
development of amyloidosis in mice (Solomon et al.
2007). There are no reports of higher prevalence of
the condition in countries with high consumption of
duck and goose liver, such as France, but there are no
goodstudiesonthefrequencyofthisdisorderanywhere.
In a recent amyloid induction study in mice, in which
we used extracts of AA-amyloid from a number of
different mammalian and one avian species, it was
obvious that species barriers may be present. Only
ﬁbrils from one species enhanced amyloidosis in most
mice (P. Westermark et al., unpublished results).
Therefore, it is quite possible that goose and duck
AA-amyloids are completely harmless for humans, but
that has to be shown.
Figure 2. A glomerulus of an amyloidotic kidney, by mistake
usedfor transplantation intoa patient with renal insufﬁciency.
Congo red in polarized light.
Review. Amyloid in PNG P. Westermark & G. T.Westermark 3703
Phil. Trans. R. Soc. B (2008)6. SEEDING OF LOCALIZED AMYLOID FORMS
Amyloid deposits are a hallmark of Alzheimer’s disease
and type 2 diabetes and are believed to be important in
the pathogenesis of the neuron and beta-cell death,
respectively, in these two conditions. Typically, these
deposits are widely spread as small particles in the brain
and the islets of Langerhans. A question is then whether
the ﬁbrils form spontaneously at each point or if they
start at one or a few sites and then spread by seeding.
Given the properties of ﬁbrils of the constituting
peptides, Ab and IAPP, to efﬁciently seed further ﬁbril
formation in vitro, it is most reasonable to believe that
spreadingoccursbyseeding,althoughtheroutesarenot
fully understood. The same should certainly be true
with the different systemic amyloidoses. We have found
that islet amyloidosis is seedable in vivo by injection of a
trace amount of preformed ﬁbrils made of synthetic
IAPP into transgenic mice that express human IAPP
(G. T. Westermark et al., unpublished results). An
importantandyetnotmuchstudiedquestioniswhether
one kind of amyloid can cross-seed and induce another
form of amyloidosis. This possibility is of interest since
small local amyloid deposits of different biochemical
nature are very common and associated with ageing
(Cornwell et al. 1995).
7. CONCLUSIONS
Much interest has been focused on kuru, and studies of
this and closely related diseases have been absolutely
crucial for our present understanding of transmissible
encephalopathies and also amyloidosis (Prusiner et al.
1983; Gajdusek 1994). When kuru now is disappearing
from Papua New Guinea (Collinge et al. 2006), other
forms of amyloidosis should attract more interest in
this country. This may be particularly true for AA-
amyloidosis, which most likely still is a serious health
problem in the Watut Valley and probably in other parts
of thecountry.Thepossibilityof ageneticpredisposition
for thediseaseaswell aspotential environmental factors,
in addition to infections, for the development of this
life-threatening condition will be important to study.
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